ClinicalTrials.gg
CompletedNCT04582227Updated Jan 17, 2024

Using Ambu Aura-i Laryngeal Mask Airway in Cranial Surgery

An observational study in Hypertension, Malignant and Airway Management, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by Cairo University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Hypertension by Cairo University — 1 open to participants now, 1 under way, none of them phase 3. Hypertension · Cairo University.

Started
2020
the only one that year
Observational
2 of 16
none open now
Registered
5th of 16
by date

Among the 16 studies in Hypertension by Cairo University, this one is the only one that started in 2020, is one of 2 observational ones, and was the 5th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 16 studies in Hypertension by Cairo University is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hypertension by Cairo University, or all of them as a file.
02

Study summary

the investigators hypothesize that Ambu aura-i LMA can be used safely in patients undergoing craniotomies and are effective in reducing the incidence of emergence hypertension.

Read the detailed description

In this study the investigators want to assess the safety of using SGA devices in cranial surgery and comparing the effect of these devices with ETT regarding hemodynamics stability throughout the procedure and intracranial tension.

03

Conditions studied

  • Hypertension, Malignant
  • Airway Management

Browse trials for

Keywords

  • Hypertension
  • airway
  • Laryngeal Mask Airway
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients aged from 18 to 60 years presented with brain lesions undergoing craniotomies under general anaesthesia in supine position.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Study will be conducted on patients undergoing craniotomies under general anaesthesia in supine position.
  2. Aged 18 to 60 years.
  3. ASA 1 or 2.
  4. GCS ≥ 13.

Exclusion criteria

Exclusion Criteria:

  1. Patients who are known hypertensive, history of cardiac diseases or chest diseases
  2. Patients with risk of aspiration (Obesity with ≥ 40, hiatal hernia, esophageal cancer and previous esophageal surgery).
  3. Risk of difficult intubation
  4. Extensive intracranial tumours that may affect recovery of patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
120 participants (actual)
Target follow-up
5 Days
Patient registry
Yes

Groups and cohorts

  • The ETT group

    Oral endotracheal intubation via direct laryngoscopy will be performed. The ETT cuff will be inflated to 25 cmH2O using a manometer.

  • The LMA group

    The Ambu aura-i LMA size will be chosen and inserted using the recommended single-handed rotational technique. Subsequently, a manometer was used to inflate the cuff to 60 cm H2O.

    Device: Ambu aura-i LMA

Interventions

  • DeviceAmbu aura-i LMA

    The ETT or the LMA will be inserted with the patient's head position is aided either by pins or head rest, and either the head will be in neutral position or tilted as long as the airway device is successfully placed.

06

What researchers measure

Primary outcomes

  1. Measure Mean blood pressure

    incidence of emergence hypertension

    Time frame: UP TO 1 HOURE

Secondary outcomes

  1. Measure Mean Heart rate

    incidence of tachycardia or bradycardia with emergence.

    Time frame: UP TO 1 HOURE

  2. successful placement of the airway device

    Number of attempts needed for successful placement of the airway device

    Time frame: UP TO 1 HOURE

  3. incidence of postoperative complication

    incidence of postoperative sore throat , hoarseness

    Time frame: up to 24 hours

  4. amount of fentanyl

    by microgram

    Time frame: up to 24 hours

07

Study locations

1 site
  • Cairo university
    Cairo, 11451, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in May 2023, 29 months.

Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's 29 months is below that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2020
First posted
Oct 9, 2020
StartActual
Dec 1, 2020
Primary completionActual
May 10, 2023
CompletionActual
Jun 22, 2023
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04582227
Lead sponsor
Cairo University
Responsible party
Amr Samir Wahdan (Lecturer of Anesthesia, Pain management and Surgical ICU, Cairo University) — Principal investigator
First posted
Oct 9, 2020
Start date
Dec 1, 2020
Primary completion
May 10, 2023
Completion
Jun 22, 2023
Last update
Jan 17, 2024

Study contacts

Amr s wahdan, MD
principal investigator · Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion